Detalhe da pesquisa
1.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
N Engl J Med;
388(4): 319-332, 2023 01 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36511784
2.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
N Engl J Med;
389(1): 33-44, 2023 Jul 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37407001
3.
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab.
Blood;
140(8): 839-850, 2022 08 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35605176
4.
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment.
Future Oncol;
20(12): 717-726, 2024 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38088119
5.
Novel combination approaches with targeted agents in frontline chronic lymphocytic leukemia.
Cancer;
129(1): 18-31, 2023 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36326285
6.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood;
137(20): 2817-2826, 2021 05 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33259589
7.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet;
397(10277): 892-901, 2021 03 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33676628
8.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood;
136(10): 1134-1143, 2020 09 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32688395
9.
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
Br J Haematol;
188(6): 918-923, 2020 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31682002
10.
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
Blood;
132(23): 2446-2455, 2018 12 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30287523
11.
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Future Oncol;
16(10): 517-523, 2020 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32207333
12.
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database.
Haematologica;
2024 Feb 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38426293
13.
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
Mol Ther;
26(8): 1896-1905, 2018 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29910179
14.
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol;
19(1): 65-75, 2018 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29246803
15.
Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Blood;
128(18): 2199-2205, 2016 11 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27601462
16.
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Blood;
138(18): 1768-1773, 2021 11 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34297826
17.
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.
Haematologica;
103(5): 874-879, 2018 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29419429
18.
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Haematologica;
103(9): 1511-1517, 2018 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29880613
19.
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
Am J Hematol;
93(11): 1394-1401, 2018 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30132965
20.
Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
Oncologist;
22(11): 1283-1291, 2017 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28851760